Find out the revenue, expenses and profit or loss over the last fiscal year. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Get the detailed quarterly/annual income statement for Cassava Sciences, Inc. (SAVA). Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. The Company develops safer and efficacious drugs for use in pain management, particularly in the area of opioid painkillers. Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The Company is focused on developing drug for the treatment of nervous system disorders. Find the latest Cassava Sciences, Inc. (SAVA) stock quote, history, news and other vital information to help you with your stock trading and investing. Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. Customizable interactive chart for Cassava Sciences Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. If you had invested in Cassava Sciences stock at $153.16, your return over the last 20 years would have been -93.43%, for an annualized return of -12.72%. Dive deeper with interactive charts and top stories of CASSAVA SCIENCES, INC.. View the latest SAVA stock quote and chart on MSN Money. Discover historical prices for SAVA stock on Yahoo Finance. AUSTIN - Cassava Sciences, Inc. (Nasdaq: SAVA) (the 'Company' or ' Cassava Sciences'), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the pricing of its previously announced underwritten public offering.. Overview Detailed Quote … SAVA, Cassava Sciences Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Cassava Sciences stock was originally listed at a price of $153.16 in Jul 14, 2000. Cassava Sciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Cassava Sciences Inc (NQ: SAVA ) 10.48-0.41 (-3.76%) Official Closing Price Updated: 7:59 PM EDT, Oct 16, 2020 Add to My Watchlist. Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is offering 9,375,000 shares of its common stock, par value $0.001 per share, at a price to the public of $8.00 per share. Cassava Sciences is seeing heavy trading of SAVA stock on the news. Get Cassava Sciences Inc (SAVA:NASDAQ) real-time stock quotes, news and financial information from CNBC. View the latest Cassava Sciences Inc. (SAVA) stock price, news, historical charts, analyst ratings and financial information from WSJ. … SAVA Cassava Sciences Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in as … Find real-time SAVA - Cassava Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third party. SAVA - Cassava Sciences Inc Stock quote - CNNMoney.com Markets Cassava Sciences, Inc. SAVA was a big mover last session, as the company saw its shares rise more than 8% on the day. Check out our SAVA stock analysis, current SAVA quote, charts, and historical prices for Cassava Sciences Inc stock Cassava Sciences recently announced final results of a Phase 2b study with sumifilam, its lead drug candidate, in Alzheimer’s disease. Quote. View the latest SAVA financial statements, income statements and financial ratios. About Alzheimer's Disease Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Cassava Sciences, Inc. develops drugs using its proprietary technology. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Enter Symbol. Cassava Sciences, Inc. (SAVA) Quote Overview » Charts » Cassava Sciences, Inc. (SAVA) Price and EPS Surprise . Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. View today's stock price, news and analysis for Cassava Sciences Inc. (SAVA). Cassava Sciences Inc SAVA Morningstar Rating Rating as of Dec 11, 2020. It is also developing an experimental biomarker diagnostic PTI-125 to detect Alzheimer's disease with the help of a blood test. Price & EPS Surprise. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Real-time exchange rate quote of Cassava Sciences Inc. - Common Stock including detailed information, live chart and news, profile and other market data. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third-party.About Alzheimer's Disease Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Cassava Sciences, Inc. Common Stock (SAVA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. A better-ranked stock in the Medical - Drugs industry is BioSpecifics Technologies Corp. BSTC, which currently carries a Zacks Rank #1 (Strong Buy). Cassava Sciences (SAVA) stock price, charts, trades & the US's most popular discussion forums. 5 Stocks Set to Double Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in … It focuses on developing product candidates intended for the treatment of Alzheimerâ€™s disease, including PTI-125 and PTI-125Dx. This stock, which remained volatile and traded within the range of $2.1200 –$9.6400 in the past one-month time frame, witnessed a sharp increase yesterday. Description: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Free forex prices, toplists, indices and lots more. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. Over 16 million shares have changed hands as of this writing, which is more … Cassava Sciences, Inc. price | Cassava Sciences, Inc. Quote. You can see the complete list of today’s Zacks #1 Rank stocks here. View daily, weekly or monthly format back to when Cassava Sciences, Inc. stock was issued. Cassava Sciences plans to announce results of an interim analysis as additional safety and cognition data is collected from patients enrolled in the open-label study. The move came on solid volume too with far more shares changing hands than in a normal session. Cassava Sciences Inc. annual stock financials by MarketWatch. Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes, effective after the close of the U.S. markets on Friday, June 26, 2020.